Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations

By Schmitz K.   Wohlschlaeger J.   Alakus H.   Bohr J.   Stauder M.   Worm K.   Winde G.   Schmid K.   Baba H.  

Virchows Archiv, Vol. 450, Iss. 2, 2007-02 ,pp. : 151-159

Springer Publishing Company

Access to resources Recommend Favorite

Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer—rarity of co-occurrence of mutations in APC, K-ras, and p53 genes

By Chiang Jy-Ming  

Virchows Archiv, Vol. 445, Iss. 5, 2004-11 ,pp. : 465-471

Springer Publishing Company

Access to resources Recommend Favorite

Plasma miR200c and miR18a as potential biomarkers for the detection of colorectal carcinoma

By Zhang   Zhou   Liu   Tian   Xia  

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 379-384

Spandidos Publications

Access to resources Recommend Favorite

A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation

By Preto Ana   Moutinho Cátia   Velho Sérgia   Oliveira Carla   Rebocho Ana   Figueiredo Joana   Soares Paula   Lopes José   Seruca Raquel  

Virchows Archiv, Vol. 450, Iss. 6, 2007-06 ,pp. : 619-626

Springer Publishing Company

Access to resources Recommend Favorite

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin or irinotecanbased treatment

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 356-362

Spandidos Publications

Access to resources Recommend Favorite